依达拉奉治疗ICU急性缺血缺氧性脑病的效果(1)
[摘要]目的 探討依达拉奉治疗ICU急性缺血缺氧性脑病的效果。方法 选取2017年1月～2019年1月来我院ICU就诊的52例急性缺血缺氧性脑病患者作为研究对象，按照随机抽签方式分为对照组(n=26)和观察组(n=26)。对照组患者采用机械辅助通气，对脑循环加以改善，维持患者的生命体征，观察组患者在对照组治疗基础上采用依达拉奉治疗。治疗2个疗程后比较两组患者的治疗效果、治疗前后的神经功能缺损评分及不良反应发生情况。结果 观察组患者的治疗总有效率(92.3%)高于对照组(73.1%)，差异有统计学意义(P<0.05);治疗前和治疗后第7天，两组患者的神经功能缺损评分比较，差异无统计学意义(P>0.05);治疗后第14、28天，两组患者的神经功能缺损评分均低于本组治疗前，且观察组患者治疗后第14、28天的神经功能缺损评分低于对照组，差异有统计学意义(P<0.05)。观察组患者的不良反应总发生率低于对照组，差异有统计学意义(P<0.05)。结论 采用依达拉奉治疗ICU急性缺血缺氧性脑病效果良好，可以改善患者的神经功能缺损，减少不良反应发生，临床具有较高应用价值。
[关键词]依达拉奉;ICU;急性缺血缺氧性脑病;治疗效果;不良反应
[中图分类号] R743.3 [文献标识码] A [文章编号] 1674-4721(2020)8(c)-0099-03
[Abstract] Objective To study the effect of Edaravone on ICU acute ischemic hypoxic encephalopathy. Methods A total of 52 patients with acute ischemic hypoxic encephalopathy from January 2017 to January 2019 in our hospital′s ICU for treatment were selected as the research objects， and were divided into control group (n=26) and observation group (n=26) according to the random drawing method. The control group was treated mechanical assisted ventilation to improve the cerebral circulation and maintain the vital signs of the patients. The observation group was treated with Edaravone based on the treatment in the control group. After two courses of treatment， the treatment effect， neurological deficit scores before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group (92.3%) was higher than that in the control group (73.1%)， the difference was statistically significant (P<0.05); before treatment and on the 7th day after treatment， the neurological deficits scores of patients in the two groups， the differences were not statistically significant (P>0.05). On the 14th and 28th days after treatment， the neurological deficit scores of the two groups of patients were lower than those of the group before treatment， and the neurological deficit scores of the observation group were lower than those of the control group on the 14th and 28th days after treatment， the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group， and the difference was statistically significant (P<0.05). Conclusion The use of Edaravone in the treatment of acute ischemic hypoxic encephalopathy in ICU has a good effect， can improve patients′ neurological deficits and reduce the occurrence of adverse reactions， and has high clinical application value., http://www.100md.com(陈曼妮)
[关键词]依达拉奉;ICU;急性缺血缺氧性脑病;治疗效果;不良反应
[中图分类号] R743.3 [文献标识码] A [文章编号] 1674-4721(2020)8(c)-0099-03
[Abstract] Objective To study the effect of Edaravone on ICU acute ischemic hypoxic encephalopathy. Methods A total of 52 patients with acute ischemic hypoxic encephalopathy from January 2017 to January 2019 in our hospital′s ICU for treatment were selected as the research objects， and were divided into control group (n=26) and observation group (n=26) according to the random drawing method. The control group was treated mechanical assisted ventilation to improve the cerebral circulation and maintain the vital signs of the patients. The observation group was treated with Edaravone based on the treatment in the control group. After two courses of treatment， the treatment effect， neurological deficit scores before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the observation group (92.3%) was higher than that in the control group (73.1%)， the difference was statistically significant (P<0.05); before treatment and on the 7th day after treatment， the neurological deficits scores of patients in the two groups， the differences were not statistically significant (P>0.05). On the 14th and 28th days after treatment， the neurological deficit scores of the two groups of patients were lower than those of the group before treatment， and the neurological deficit scores of the observation group were lower than those of the control group on the 14th and 28th days after treatment， the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group， and the difference was statistically significant (P<0.05). Conclusion The use of Edaravone in the treatment of acute ischemic hypoxic encephalopathy in ICU has a good effect， can improve patients′ neurological deficits and reduce the occurrence of adverse reactions， and has high clinical application value., http://www.100md.com(陈曼妮)